Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock

Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock...

Descripción completa

Detalles Bibliográficos
Autores: Hongisto, Mari|||0000-0002-9838-1248, Lassus, Johan, Tarvasmäki, Tuukka|||0000-0003-3406-243X, Sans-Roselló, Jordi|||0000-0003-3176-6191, Tolppanen, Heli|||0000-0002-3364-8554, Kataja, Anu, Jäntti, Toni|||0000-0001-8348-0844, Sabell, Tuija|||0000-0003-2764-7253, Banaszewski, Marek, Silva-Cardoso, Jose, Parissis, John, Jurkko, Raija, Spinar, Jindrich, Castrén, Maaret|||0000-0001-7164-4733, Mebazaa, Alexandre|||0000-0001-8715-7753, Masip, Josep|||0000-0002-8612-9889, Harjola, Veli-Pekka
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:268213
Acceso en línea:https://ddd.uab.cat/record/268213
https://dx.doi.org/urn:doi:10.1093/ehjacc/zuac096
Access Level:acceso abierto
Palabra clave:Cardiogenic shock
Supar
Risk stratification
Biomarker
Descripción
Sumario:Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.

Similares en LA Referencia